4//SEC Filing
Easom Eric 4
Accession 0000950170-25-030041
CIK 0001880438other
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 4:22 PM ET
Size
9.8 KB
Accession
0000950170-25-030041
Insider Transaction Report
Form 4
Easom Eric
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2025-02-26+145,250→ 246,380 total - Award
Stock Option (right to buy)
2025-02-26+290,500→ 290,500 totalExercise: $1.13Exp: 2035-02-25→ Common Stock (290,500 underlying)
Holdings
- 97,058(indirect: See Footnote)
Common Stock
- 97,058(indirect: See Footnote)
Common Stock
- 1,065,766(indirect: See Footnote)
Common Stock
Footnotes (6)
- [F1]Represents restricted stock units ("RSUs") which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
- [F2]Includes a balance of 99,000 RSUs which vest as follows: 1/4th of the shares vests annually over four years from January 1, 2024, subject to the Reporting Person's continuous service as of each such date.
- [F3]Consists of shares of Common Stock held by the Easom Living Trust dated August 21, 2019.
- [F4]Consists of shares of Common Stock held by the C. Easom Irrevocable Trust dated October 8, 2021.
- [F5]Consists of shares of Common Stock held by the Jude Easom Irrevocable Trust dated October 8, 2021.
- [F6]The shares subject to the option vest as follows: 1/48th of the shares vests monthly over four years from January 1, 2025, subject to the Reporting Person's continuous service as of such date.
Documents
Issuer
AN2 Therapeutics, Inc.
CIK 0001880438
Entity typeother
Related Parties
1- filerCIK 0001914503
Filing Metadata
- Form type
- 4
- Filed
- Feb 27, 7:00 PM ET
- Accepted
- Feb 28, 4:22 PM ET
- Size
- 9.8 KB